NucleoCapture is a non-pyrogenic, sterile, single-use medical device. It is an extracorporeal adsorption column for the removal of cell-free DNA (cfDNA) from plasma. 

The column is the sole device developed by Santersus AG and the sole subject of our certification. It operates in conjunction with a therapeutic apheresis system, which is a separate product supplied and CE marked by its own manufacturer. Santersus AG does not develop, manufacture or supply apheresis systems. The column is integrated into the extracorporeal circuit downstream from where the plasma is separated.

The sorbent comprises crosslinked agarose beads with a covalently immobilised ligand on their surface. The ligand is recombinant human histone 1.3 protein (rhH1.3 protein), which has high affinity for cfDNA. The ligand is not released and does not enter the patient’s circulation. 

NucleoCapture is an investigational medical device. It must be used exclusively within the framework of a clinical investigation plan, by qualified healthcare professionals sufficiently trained and experienced in therapeutic apheresis.

In preclinical testing, a single pass of plasma through the NucleoCapture column removed over 95% of NETs.

In contrast to any potential pharmacological intervention targeting NETs, Santersus’ technology allows safe removal of NETs from plasma without compromising the defensive function of neutrophils.